Search clinical trials for: Epinephrine HFA-MDI (E004)

Total 94 results

AstraZeneca

Completed

Study to Assess Bronchospasm Potentially Induced by HFO vs HFA MDI in Participants With Well/Partially Controlled Asthma

Asthma

United States
AstraZeneca

Completed

Study to Assess Effect of HFO MDI Propellant on Mucociliary Clearance Vs. HFA MDI Propellant in Healthy Participants

Mucociliary Clearance

United States, United Kingdom
Amphastar Pharmaceuticals, Inc.

Terminated

Randomized, Placebo/Active Crossover Dose-ranging Study for Safety and Efficacy in Asthma Patients.

Asthma

United States
AstraZeneca

Completed

A Study to Assess the Safety of Budesonide/Glycopyrronium/Formoterol Fumarate With the Hydrofluoroolefin Propellant in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease (COPD)

United States, Canada, Germany, Argentina, Bulgaria, Poland, Turkey, Mexico, United Kingdom
Amphastar Pharmaceuticals, Inc.

Completed

Evaluation of Efficacy and Safety for Single Dose of E004 in Children With Asthma

Asthma

United States
Amphastar Pharmaceuticals, Inc.

Completed

Evaluation of Efficacy and Safety of E004 in Children With Asthma

Asthma

United States
AstraZeneca

Recruiting

A Study to Investigate the Effect on Lung Function of BDA Formulated With a New Propellant (HFO) Compared With an Approved Asthma Treatment (BDA With HFA Propellant) in Participants With Asthma

Asthma

United States, Vietnam, China, Mexico, Thailand, Malaysia, United Arab Emirates, United Kingdom
AstraZeneca
Parexel

Not yet recruiting

A Study to Assess the Lung Exposure Bioequivalence of Budesonide, Glycopyrronium, & Formoterol (BGF) Metered Dose Inhaler (MDI) Hydrofluoroolefin (HFO) With a Spacer (Treatment B), BGF MDI Hydrofluoroalkane (HFA) With a Spacer (Treatment A), as Well as BGF MDI HFO Without a Spacer (Treatment C)

Healthy

Germany
AstraZeneca
Parexel

Completed

A Study to Assess the Pharmacokinetics and Safety of Budesonide, Glycopyrronium, & Formoterol (BGF) Metered Dose Inhaler (MDI) Hydrofluoroolefin (HFO) With a Spacer (Treatment B), BGF MDI Hydrofluoroalkane (HFA) With a Spacer (Treatment A), as Well as BGF MDI HFO Without a Spacer (Treatment C).

Chronic Obstructive Pulmonary Disease

Germany
AstraZeneca

Completed

Study to Assess the Pharmacokinetic Bioequivalence of Budesonide and Albuterol With an Alternate Propellant Compared to Current Propellant.

Heathy Participants

United States
Boehringer Ingelheim

Completed

Safety and Tolerability of COMBIVENT® HFA as Compared to COMBIVENT® CFC and Placebo HFA in Healthy Male and Female Subjects

Healthy
Sunovion

Completed

Safety and Tolerability Study of Levalbuterol HFA and Racemic Albuterol HFA in Pediatrics Subjects With Asthma

Asthma

United States
AstraZeneca

Recruiting

A Study to Investigate the Effect on Lung Function of an Approved COPD Treatment (BGF, With HFA Propellant) Compared to BGF Formulated With a New Propellant (HFO) in Participants 40 to 80 Years of Age With COPD

COPD (Chronic Obstructive Pulmonary Disease)

United States, Korea, Republic of, Argentina, Turkey, Vietnam, Malaysia, Philippines, Thailand, Hungary, Mexico, Bulgaria, Canada, India, Poland
GlaxoSmithKline

Completed

Efficacy and Safety of Fluticasone Propionate(FP)/ Salmeterol Xinafoate (SLM) Hydro Fluoro Alkane (HFA) Metered Dose Inhaler (MDI) in Pediatric Patients With Bronchial Asthma

Asthma

Japan
Amphastar Pharmaceuticals, Inc.

Completed

Epinephrine Inhalation Aerosol USP, a HFA-MDI Study for Assessment of Pharmacokinetics

Asthma | Shortness of Breath | Wheezing | Bronchospasm

United States
Amphastar Pharmaceuticals, Inc.

Terminated

Single-Dose Cross-Over Study of the Effects of Albuterol-HFA in Exercise Induced Bronchoconstriction

Asthma | Bronchospasm

United States
Genocea Biosciences, Inc.

Completed

Safety and Immunogenicity Study of Prophylactic Streptococcus Pneumoniae Vaccine

Streptococcus Pneumoniae

United States
AstraZeneca
Parexel

Completed

A Study to Assess Drug Absorption of Fixed Dose Combinations of Budesonide, Glycopyrronium, and Formoterol

Chronic Obstructive Pulmonary Disease (COPD)

United States
Amphastar Pharmaceuticals, Inc.

Completed

Epinephrine Inhalation Aerosol USP, CLINICAL STUDY-B3 FOR ASSESSMENT OF PHARMACOKINETICS

Asthma

United States
Sunovion

Completed

Safety and Tolerability Study of Levalbuterol HFA Compared to Racemic Albuterol HFA in Subjects With Asthma

Asthma

United States
AstraZeneca
Parexel

Completed

A Study to Assess the Total Systemic Exposure Bioequivalence of of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI HFO Compared With BGF MDI HFA

Chronic Obstructive Pulmonary Disease

United States
Sunovion

Completed

A Safety and Tolerability Study of Levalbuterol HFA Metered Dose Inhaler in Subjects With Asthma

Asthma

United States
Amphastar Pharmaceuticals, Inc.

Completed

Epinephrine Inhalation Aerosol USP: For Evaluation Of Efficacy And Safety In Asthma Patients

Asthma

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Comparative Effectiveness of a Breath-operated Albuterol Inhaler in Asthma Patients With Poor Inhaler Technique

Asthma

United States
University of Florida
GlaxoSmithKline

Completed

Effect of Age and Device on Delivery of Fluticasone

Asthma

United States
Chiesi Farmaceutici S.p.A.

Completed

Study to Assess the Effect of the New HFA-152a Propellant on Mucociliary Clearance

Mucociliary Clearance

United Kingdom
Lupin, Inc.

Completed

Pharmacodynamic Bioequivalence of Metered Dose Inhalers of Albuterol Sulfate in Patients With Stable Mild Asthma

Mild Persistent Asthma

United States
AstraZeneca
Parexel

Completed

Study to Assess the Lung Exposure Bioequivalence of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI HFO Compared With BGF MDI HFA

Chronic Obstructive Pulmonary Disease

United States
Sunovion

Completed

Long Term Safety Study of Levalbuterol and Racemic Albuterol in Subjects Twelve Years of Age and Older With Asthma

Asthma

United States, Canada
Pneumacare Ltd
Cambridge University Hospitals NHS Foundation Trust; University of Cambridge; Norfolk and Suffolk Primary and Community Care and other collaborators

Unknown

Thora-3Di™ Respiratory Rate Validation

Pulmonary Disease

United Kingdom
University of Florida
GlaxoSmithKline

Completed

Impact of Anti-static Chamber/Mask

Asthma

United States
Amphastar Pharmaceuticals, Inc.

Terminated

Assessment and Evaluation of Pharmacokinetic Profile of E004 in Healthy Adults

Asthma

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Comparison of Two Bronchodilator Inhalers in Adolescents and Adults With Exercise-Induced Asthma

Exercise-induced Bronchospasm

United States
Concentrx Pharmaceuticals, Inc.
PharPoint Research, Inc.; Kramer Consulting, LLC

Completed

Safety and Pharmacokinetics of Halix(TM) Albuterol Unit Dose Disposable Inhaler Versus Albuterol MDI

Asthma

United States
Boehringer Ingelheim

Terminated

Respimat® Inhaler vs a Metered Dose Inhaler Using Berodual® in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Comparison of Single-Dose Efficacy of an Albuterol Breath-Actuated Inhaler (Albuterol-HFA-BAI) Versus an Albuterol Metered-Dose Inhaler (Albuterol-HFA-MDI) in Participants With Asthma

Asthma

United States
Children's Hospital of Eastern Ontario
The Hospital for Sick Children; Canadian Institutes of Health Research (CIHR); Alberta Children's Hospital Research Institute and other collaborators

Recruiting

Bronchiolitis in Infants Placebo Versus Epinephrine and Dexamethasone Study (BIPED)

Bronchiolitis

Canada, New Zealand, Australia
IRCCS Azienda Ospedaliero-Universitaria di Bologna

Unknown

Mid-HDF Randomized Controlled Study on Outcome (MILESTONE)

End Stage Renal Disease

Spain, France, Italy, Belgium
Amphastar Pharmaceuticals, Inc.

Completed

Study of Drug Exposure in Systemic Circulation of Primatene Mist by Oral Inhalation, Versus Epinephrine Injection by Intramuscular Injection and ProAir by Oral Inhalation in Healthy Individuals

Asthma | Pharmacokinetics | Anaphylaxis | Epinephrine | Albuterol

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A Dose-ranging Study to Evaluate Albuterol and Hydrofluoroalkane in Subjects Ages 12 and Older With Persistent Asthma

Asthma

United States
Pearl Therapeutics, Inc.

Completed

PT001 MDI Versus Atrovent Study in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

United States
Merck Sharp & Dohme LLC

Completed

Efficacy and Safety Study of RAGWITEK™ (MK-3641) in Children With Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (MK-3641-008)

Rhinitis, Allergic, Seasonal
Sunovion

Completed

Reliability of a Top Mount Actuation Indicator With Levalbuterol MDI in Adult and Pediatric Subjects With Asthma or COPD

Chronic Obstructive Pulmonary Disease | Asthma | COPD

United States
The Cleveland Clinic

Completed

Measure of Frailty in Perioperative Setting

Frailty

United States
CHU de Reims

Completed

Association Between Hidradenitis Suppurativa and Spondyloarthritis (VESPA)

Hidradenitis Suppurativa

France
FLUIDDA nv

Completed

Compare the Effects of Seretide® Evohaler and a Generic Salmeterol/Fluticasone Hydrofluoroalkane (HFA) Pressurized Metered-dose Inhaler (pMDI) on Functional Respiratory Imaging Parameters in Asthmatic Patients

Asthma

Belgium
Boehringer Ingelheim

Completed

Combivent® CFC Metered Dose Inhaler (MDI) in Moderate to Severe Asthma

Asthma

United States
Sunovion

Completed

Efficacy Study of Single-Dose Levalbuterol Tartrate HFA MDI Vs Placebo in Subjects 18 Years and Older With EIB

Exercise-induced Bronchospasm

United States
Boehringer Ingelheim

Completed

4 Week 2 Way Crossover Double Blind Treatment Phase With Combivent CFC Versus Albuterol Followed by a 4 Week Open Label Combivent Respimat When All Drugs Are Used for Symptom Relief as Needed in Pts With Moderate to Severe Asthma

Asthma

United States
Boehringer Ingelheim

Completed

Serial Lung Function Measurements in Healthy and Mild Asthmatic Adults After Oral Inhalation of Ethanolic Solutions Containing Two Concentrations of the Excipient Butylated Hydroxytoluene (BHT) Administered With the Respimat® B (RMT-B)

Asthma

3

Subscribe